Nexalin shareholders approve reverse stock split amendment with board discretion on ratio

Nexalin Technology, Inc.

Special meeting held March 7, 2024; 4,587,248 shares present (61.7% of outstanding).
Proposal 1 (reverse split amendment): 4,304,448 for, 259,736 against, 23,064 abstained — approved.
Board retains authority to determine if and when to file the amendment and the split ratio.
Proposal 2 (adjournment): 4,442,221 for, 112,047 against, 32,980 abstained — approved.
No specific split ratio disclosed; potential to regain compliance with Nasdaq listing standards.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Nexalin Technology, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation, as amended to date (the “Reverse Stock Split Amendment”), to effect a reverse stock split of the Company’s common stock and give the Company’s Board of Directors the authority to determine whether filing such Reverse Stock Split at the 2024-03-07 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2024-03-07

Exact text from the filing

Proposal One: Approval of an amendment to the Company’s Certificate of Incorporation, as amended to date (the “ Reverse Stock Split Amendment ”), to effect a reverse stock split of the Company’s common stock and give the Company’s Board of Directors the authority to determine whether filing such Reverse Stock Split Amendment is necessary and, if so, the ratio of such split: For Against Abstained 4,304,448 259,736 23,064

View on SEC.gov

1640 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Nexalin Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-24-001749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.